Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.

Schlapbach A, Revesz L, Pissot Soldermann C, Zoller T, Régnier CH, Bornancin F, Radimerski T, Blank J, Schuffenhauer A, Renatus M, Erbel P, Melkko S, Heng R, Simic O, Endres R, Wartmann M, Quancard J.

Bioorg Med Chem Lett. 2018 Jul 1;28(12):2153-2158. doi: 10.1016/j.bmcl.2018.05.017. Epub 2018 May 9.

PMID:
29759726
2.

The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibition.

Bardet M, Unterreiner A, Malinverni C, Lafossas F, Vedrine C, Boesch D, Kolb Y, Kaiser D, Glück A, Schneider MA, Katopodis A, Renatus M, Simic O, Schlapbach A, Quancard J, Régnier CH, Bold G, Pissot-Soldermann C, Carballido JM, Kovarik J, Calzascia T, Bornancin F.

Immunol Cell Biol. 2018 Jan;96(1):81-99. doi: 10.1111/imcb.1018. Epub 2017 Dec 21.

PMID:
29359407
3.

Two Antagonistic MALT1 Auto-Cleavage Mechanisms Reveal a Role for TRAF6 to Unleash MALT1 Activation.

Ginster S, Bardet M, Unterreiner A, Malinverni C, Renner F, Lam S, Freuler F, Gerrits B, Voshol J, Calzascia T, Régnier CH, Renatus M, Nikolay R, Israël L, Bornancin F.

PLoS One. 2017 Jan 4;12(1):e0169026. doi: 10.1371/journal.pone.0169026. eCollection 2017.

4.

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.

Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G, Woytschak J, Regnier CH, Katopodis A, Boyman O.

Sci Transl Med. 2016 Nov 30;8(367):367ra166.

PMID:
27903862
5.

The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-κB signalling.

Klein T, Fung SY, Renner F, Blank MA, Dufour A, Kang S, Bolger-Munro M, Scurll JM, Priatel JJ, Schweigler P, Melkko S, Gold MR, Viner RI, Régnier CH, Turvey SE, Overall CM.

Nat Commun. 2015 Nov 3;6:8777. doi: 10.1038/ncomms9777.

6.

Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation.

Bornancin F, Renner F, Touil R, Sic H, Kolb Y, Touil-Allaoui I, Rush JS, Smith PA, Bigaud M, Junker-Walker U, Burkhart C, Dawson J, Niwa S, Katopodis A, Nuesslein-Hildesheim B, Weckbecker G, Zenke G, Kinzel B, Traggiai E, Brenner D, Brüstle A, St Paul M, Zamurovic N, McCoy KD, Rolink A, Régnier CH, Mak TW, Ohashi PS, Patel DD, Calzascia T.

J Immunol. 2015 Apr 15;194(8):3723-34. doi: 10.4049/jimmunol.1402254. Epub 2015 Mar 11.

7.

The identification and characterization of a STAT5 gene signature in hematologic malignancies.

Sonkin D, Palmer M, Rong X, Horrigan K, Regnier CH, Fanton C, Holash J, Pinzon-Ortiz M, Squires M, Sirulnik A, Radimerski T, Schlegel R, Morrissey M, Cao ZA.

Cancer Biomark. 2015;15(1):79-87. doi: 10.3233/CBM-140434.

PMID:
25524945
8.

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

Andraos R, Qian Z, Bonenfant D, Rubert J, Vangrevelinghe E, Scheufler C, Marque F, Régnier CH, De Pover A, Ryckelynck H, Bhagwat N, Koppikar P, Goel A, Wyder L, Tavares G, Baffert F, Pissot-Soldermann C, Manley PW, Gaul C, Voshol H, Levine RL, Sellers WR, Hofmann F, Radimerski T.

Cancer Discov. 2012 Jun;2(6):512-523. doi: 10.1158/2159-8290.CD-11-0324. Epub 2012 May 3.

9.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM.

J Exp Med. 2012 Feb 13;209(2):259-73. doi: 10.1084/jem.20111694. Epub 2012 Jan 23.

10.

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.

Baffert F, Régnier CH, De Pover A, Pissot-Soldermann C, Tavares GA, Blasco F, Brueggen J, Chène P, Drueckes P, Erdmann D, Furet P, Gerspacher M, Lang M, Ledieu D, Nolan L, Ruetz S, Trappe J, Vangrevelinghe E, Wartmann M, Wyder L, Hofmann F, Radimerski T.

Mol Cancer Ther. 2010 Jul;9(7):1945-55. doi: 10.1158/1535-7163.MCT-10-0053. Epub 2010 Jun 29.

11.

Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.

Pissot-Soldermann C, Gerspacher M, Furet P, Gaul C, Holzer P, McCarthy C, Radimerski T, Regnier CH, Baffert F, Drueckes P, Tavares GA, Vangrevelinghe E, Blasco F, Ottaviani G, Ossola F, Scesa J, Reetz J.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2609-13. doi: 10.1016/j.bmcl.2010.02.056. Epub 2010 Feb 19.

PMID:
20231096
12.

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.

Gerspacher M, Furet P, Pissot-Soldermann C, Gaul C, Holzer P, Vangrevelinghe E, Lang M, Erdmann D, Radimerski T, Regnier CH, Chene P, De Pover A, Hofmann F, Baffert F, Buhl T, Aichholz R, Blasco F, Endres R, Trappe J, Drueckes P.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1724-7. doi: 10.1016/j.bmcl.2010.01.069. Epub 2010 Jan 21.

PMID:
20138510
13.

Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome.

Bienaime F, Dragon-Durey MA, Regnier CH, Nilsson SC, Kwan WH, Blouin J, Jablonski M, Renault N, Rameix-Welti MA, Loirat C, Sautés-Fridman C, Villoutreix BO, Blom AM, Fremeaux-Bacchi V.

Kidney Int. 2010 Feb;77(4):339-49. doi: 10.1038/ki.2009.472. Epub 2009 Dec 16.

14.

Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome.

Roumenina LT, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-Durey MA, Cayla M, Fridman WH, Macher MA, Ribes D, Moulonguet L, Rostaing L, Satchell SC, Mathieson PW, Sautes-Fridman C, Loirat C, Regnier CH, Halbwachs-Mecarelli L, Fremeaux-Bacchi V.

Blood. 2009 Sep 24;114(13):2837-45. doi: 10.1182/blood-2009-01-197640. Epub 2009 Jul 7.

15.

Characterization of immune functions in TRAF4-deficient mice.

Cherfils-Vicini J, Vingert B, Varin A, Tartour E, Fridman WH, Sautès-Fridman C, Régnier CH, Cremer I.

Immunology. 2008 Aug;124(4):562-74. doi: 10.1111/j.1365-2567.2008.02810.x. Epub 2008 Feb 18.

16.

Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited.

Rameix-Welti MA, Régnier CH, Bienaimé F, Blouin J, Schifferli J, Fridman WH, Sautès-Fridman C, Frémeaux-Bacchi V.

Eur J Immunol. 2007 May;37(5):1377-85.

17.

TRAF4 overexpression is a common characteristic of human carcinomas.

Camilleri-Broët S, Cremer I, Marmey B, Comperat E, Viguié F, Audouin J, Rio MC, Fridman WH, Sautès-Fridman C, Régnier CH.

Oncogene. 2007 Jan 4;26(1):142-7. Epub 2006 Jun 26.

PMID:
16799635
18.

Metastatic Lymph Node 51, a novel nucleo-cytoplasmic protein overexpressed in breast cancer.

Degot S, Régnier CH, Wendling C, Chenard MP, Rio MC, Tomasetto C.

Oncogene. 2002 Jun 27;21(28):4422-34.

19.

Impaired neural tube closure, axial skeleton malformations, and tracheal ring disruption in TRAF4-deficient mice.

Régnier CH, Masson R, Kedinger V, Textoris J, Stoll I, Chenard MP, Dierich A, Tomasetto C, Rio MC.

Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5585-90. Epub 2002 Apr 9. Erratum in: Proc Natl Acad Sci U S A 2002 Jun11;99(12):8457.

20.

Transcription regulation and protein subcellular localization of the truncated basic hair keratin hHb1-DeltaN in human breast cancer cells.

Boulay A, Régnier CH, Anglard P, Stoll I, Tomasetto C, Rio MC.

J Biol Chem. 2001 Jun 22;276(25):22954-64. Epub 2001 Apr 13.

21.

Expression of a truncated form of hHb1 hair keratin in human breast carcinomas.

Régnier CH, Boulay A, Asch PH, Wendling C, Chenard MP, Tomasetto C, Rio MC.

Br J Cancer. 1998 Dec;78(12):1640-4.

22.

Lasp-1, a novel type of actin-binding protein accumulating in cell membrane extensions.

Schreiber V, Moog-Lutz C, Régnier CH, Chenard MP, Boeuf H, Vonesch JL, Tomasetto C, Rio MC.

Mol Med. 1998 Oct;4(10):675-87.

23.

TRAF-4 expression in breast carcinomas.

Tomasetto C, Regnier CH, Rio MC.

Am J Pathol. 1998 Dec;153(6):2007-8. No abstract available.

24.

Tumor necrosis factor receptor associated factor 4 (TRAF4) expression pattern during mouse development.

Masson R, Régnier CH, Chenard MP, Wendling C, Mattei MG, Tomasetto C, Rio MC.

Mech Dev. 1998 Feb;71(1-2):187-91.

25.
26.

Identification and characterization of an IkappaB kinase.

Régnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M.

Cell. 1997 Jul 25;90(2):373-83.

27.

MLN64 exhibits homology with the steroidogenic acute regulatory protein (STAR) and is over-expressed in human breast carcinomas.

Moog-Lutz C, Tomasetto C, Régnier CH, Wendling C, Lutz Y, Muller D, Chenard MP, Basset P, Rio MC.

Int J Cancer. 1997 Apr 10;71(2):183-91.

28.

Expression pattern of human hair keratin basic 1 (hHb1) in hair follicle and pilomatricoma.

Régnier CH, Asch PH, Grosshans E, Rio MC.

Exp Dermatol. 1997 Apr;6(2):87-90.

PMID:
9209890
29.

Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer.

Bièche I, Tomasetto C, Régnier CH, Moog-Lutz C, Rio MC, Lidereau R.

Cancer Res. 1996 Sep 1;56(17):3886-90.

30.

Stromelysin-3 in the biology of the normal and neoplastic mammary gland.

Rio MC, Lefebvre O, Santavicca M, Noël A, Chenard MP, Anglard P, Byrne JA, Okada A, Régnier CH, Masson R, Bellocq JP, Basset P.

J Mammary Gland Biol Neoplasia. 1996 Apr;1(2):231-40. Review.

PMID:
10887496
31.

Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma.

Régnier CH, Tomasetto C, Moog-Lutz C, Chenard MP, Wendling C, Basset P, Rio MC.

J Biol Chem. 1995 Oct 27;270(43):25715-21.

32.

Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains.

Tomasetto C, Moog-Lutz C, Régnier CH, Schreiber V, Basset P, Rio MC.

FEBS Lett. 1995 Oct 16;373(3):245-9.

33.

Comparative expression of the psoriasin (S100A7) and S100C genes in breast carcinoma and co-localization to human chromosome 1q21-q22.

Moog-Lutz C, Bouillet P, Régnier CH, Tomasetto C, Mattei MG, Chenard MP, Anglard P, Rio MC, Basset P.

Int J Cancer. 1995 Oct 9;63(2):297-303.

PMID:
7591220
34.

Effect of vesical outlet obstruction on detrusor contractility and passive properties in rabbits.

Ghoniem GM, Regnier CH, Biancani P, Johnson L, Susset JG.

J Urol. 1986 Jun;135(6):1284-9.

PMID:
3712588
35.

Abnormal urethral compliance in females diagnosis, results and treatment. Preliminary study.

Susset JG, Ghoniem GM, Regnier CH.

J Urol. 1983 May;129(5):1063-5.

PMID:
6682902
36.

A new catheter to measure urethral compliance in females: normal values.

Regnier CH, Susset JG, Ghoniem GM, Biancani P.

J Urol. 1983 May;129(5):1060-2.

PMID:
6682901
37.

Effect of diethylstilbestrol on bladder contractility in male rats.

Ghoniem GM, Regnier CH, Biancani P, Susset JG.

J Urol. 1983 Apr;129(4):865-8.

PMID:
6842727
38.

The elastic behavior of the urinary bladder for large deformations.

Regnier CH, Kolsky H, Richardson PD, Ghoniem GM, Susset JG.

J Biomech. 1983;16(11):915-22.

PMID:
6654920
39.

The stop-flow technique: a way to measure detrusor strength.

Susset JG, Brissot RB, Regnier CH.

J Urol. 1982 Mar;127(3):489-94.

PMID:
7062424
40.

Viscoelastic properties of bladder strips: standardization of a technique.

Susset JG, Regnier CH.

Invest Urol. 1981 May;18(8):445-50.

PMID:
7228578

Supplemental Content

Loading ...
Support Center